|1.||Reilly, Raymond M: 12 articles (11/2015 - 03/2006)|
|2.||Dahle, Jostein: 12 articles (01/2015 - 02/2006)|
|3.||Brechbiel, Martin W: 11 articles (02/2011 - 05/2002)|
|4.||Seidl, Christof: 10 articles (03/2015 - 05/2003)|
|5.||Goldenberg, David M: 10 articles (01/2015 - 11/2003)|
|6.||Larsen, Roy H: 8 articles (01/2015 - 02/2006)|
|7.||Damle, Nitin K: 8 articles (04/2011 - 08/2003)|
|8.||Bruchertseifer, Frank: 7 articles (03/2015 - 08/2007)|
|9.||Morgenstern, Alfred: 7 articles (03/2015 - 12/2006)|
|10.||Press, Oliver W: 7 articles (10/2014 - 06/2007)|
10/05/2015 - "Ultimately, this pretargeted PET imaging strategy boasts a dramatically improved pharmacokinetic profile compared to our first generation system and is capable of clearly delineating tumor tissue with high image contrast at only a fraction of the radiation dose created by directly labeled radioimmunoconjugates. "
12/01/1998 - "To achieve maximum retention of radiolabel in tumor and a more rapid clearance of radioisotope from normal tissues, six linker immunoconjugates were evaluated in studies using nude mice and beagle dogs. "
01/01/2007 - "This can be achieved by rapid clearance of radiometal in the circulation after accumulation of radioimmunoconjugates (RIC) in the tumor. "
01/01/2003 - "Other structural manipulations that improve the selective targeting properties and rapid systemic clearance of immunoconjugates should lead to the design of effective new treatments, particularly for solid tumors."
06/01/1987 - "However, many obstacles still have to be overcome before immunoconjugates become a valuable agent in the treatment of human diseases including cancer."
01/01/1997 - "Preliminary clinical studies have clearly demonstrated the ability of radioimmunoconjugates, especially when administered at high dose followed by bone marrow rescue, to induce durable complete remission in patients with non-Hodgkin's lymphomas refractory to conventional therapies. "
12/15/1997 - "Lymphomas have been shown to be responsive to 131I immunoconjugates in studies conducted in mice and patients. "
02/15/2010 - "One strategy involves the use of radiolabeled immunoconjugates that specifically localize radiation delivery to sites of lymphoma while minimizing toxicity to normal tissues. "
09/15/2007 - "In vitro, this radioimmunoconjugate killed lymphoma cells at Becquerel per milliliter (Bq/mL) levels. "
02/01/2006 - "The alpha-emitting radioimmunoconjugate (227)Th-DOTA-p-benzyl-rituximab is a new potential anti-lymphoma agent that might overcome some of these difficulties. "
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
11/01/2004 - "The safety and efficacy of anti-CD20 in the treatment of indolent and aggressive B-cell non-Hodgkin lymphoma at any stage of disease, either as a single agent or as part of multimodality regimes, as an unconjugated antibody or as radioimmunoconjugate have changed dramatically our treatment strategies. "
01/01/2000 - "Studies further defined the role monoclonal antibody treatment for non-Hodgkin's lymphoma and more mature data were presented on both unconjugated antibody therapy and radioimmunoconjugates. "
01/01/2015 - "177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. "
03/01/2013 - "Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma."
01/01/2003 - "To date, 90Y-ibritumomab tiuxetan and 131I-tositumomab are the only FDA-approved, and most extensively studied, radioimmunoconjugates for RIT of non-Hodgkin's lymphoma (NHL). "
01/01/1997 - "Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates."
10/15/1991 - "In this study, the breast carcinoma-reactive monoclonal antibody 15A8 and a site-specific immunoconjugate of the antibody, 15A8-glycyl-tyrosyl-(N-epsilon-diethylenetriamine pentaacetic acid)-lysine (15A8-GYK-DTPA), were characterized by immunohistological methods for reactivity with normal and neoplastic human tissues and normal cynomolgus monkey tissues. "
08/01/2013 - "We examined micrometastases from a murine model of ovarian carcinoma after injection of a radioimmunoconjugate labeled with (211)At for TAT. "
09/02/2009 - "The 1C1-mcMMAF immunoconjugate had antitumor activity in preclinical models of ovarian carcinoma."
08/15/2003 - "The radioimmunoconjugate was tested for immunoreactivity, internalization, and cytotoxicity using a human ovarian carcinoma cell line, SKOV3. "
|5.||Breast Neoplasms (Breast Cancer)
10/01/1999 - "Radioimmunoconjugates of 170H.82 (m170), a panadenocarcinoma monoclonal antibody, are effective for imaging primary and metastatic breast cancer. "
10/01/2015 - "These radioimmunoconjugates (230 and 460 kBq) showed a significant higher cytotoxicity to SKBR3 human breast cancer cells overexpressing HER2 compared to (111)In-trastuzumab. "
07/01/2014 - "Immunoconjugates in the treatment of breast cancer."
12/06/2010 - "These immunoconjugates were analyzed by SDS-PAGE, and their immunoreactivity was assessed by flow cytometry using HER-2 overexpressing SK-BR-3 breast cancer cells. "
01/01/2007 - "Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells."
|8.||CMC544 (Inotuzumab Ozogamicin)
|10.||tumor-associated antigen 72
|1.||Heterologous Transplantation (Xenotransplantation)